AR051597A1 - Moduladores de los receptores de estrogeno - Google Patents
Moduladores de los receptores de estrogenoInfo
- Publication number
- AR051597A1 AR051597A1 ARP050104441A ARP050104441A AR051597A1 AR 051597 A1 AR051597 A1 AR 051597A1 AR P050104441 A ARP050104441 A AR P050104441A AR P050104441 A ARP050104441 A AR P050104441A AR 051597 A1 AR051597 A1 AR 051597A1
- Authority
- AR
- Argentina
- Prior art keywords
- disease
- estrogen
- compounds
- cognitive impairment
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C251/44—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups being part of a ring other than a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
- C07C45/676—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton by elimination of carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/69—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by addition to carbon-to-carbon double or triple bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
- C07C49/747—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
- C07C49/755—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/86—Ring systems containing bridged rings containing four rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/93—Spiro compounds
- C07C2603/95—Spiro compounds containing "not free" spiro atoms
- C07C2603/96—Spiro compounds containing "not free" spiro atoms containing at least one ring with less than six members
- C07C2603/97—Spiro compounds containing "not free" spiro atoms containing at least one ring with less than six members containing five-membered rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
Abstract
La presente se refiere a compuestos y sus derivados, su síntesis y su uso como moduladores de los receptores e estrogeno. Los compuestos de la presente son ligandos para los receptores de estrogeno y como tales pueden ser de utilidad para el tratamiento o prevencion de una variedad de afecciones relacionadas con las funciones del estrogeno que incluyen: pérdida osea, fracturas oseas, osteroporosis, enfermedad osea metastásica, enfermedad de Paget, enfermedad priodontal, degeneracion del cartílogo, endometriosis, enfermedad fibroide uterina, sofocos, niveles aumentdaos de colesterol LDL, enfermedad cardiovascular, deterioro de la funcion cognitiva, deterioro cognitivo leve asociado a la edad, trastornos degenerativos cerebrales, restenosis, ginecomastía, proliferacion de células de musculo liso vascular, obesidad, incontinencia, inflamacion, enfermedad inflamatoria del intestino, síndrome del intestino irritable, disfuncion sexual, hipertension, degeneracio retiniana y cáncer, en particular de mama, utero y prostata.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62391004P | 2004-11-01 | 2004-11-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR051597A1 true AR051597A1 (es) | 2007-01-24 |
Family
ID=35759216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050104441A AR051597A1 (es) | 2004-11-01 | 2005-10-24 | Moduladores de los receptores de estrogeno |
Country Status (16)
Country | Link |
---|---|
US (1) | US7151196B2 (es) |
EP (1) | EP1809594A1 (es) |
JP (1) | JP2008518960A (es) |
KR (1) | KR20070083896A (es) |
CN (1) | CN101068764B (es) |
AR (1) | AR051597A1 (es) |
AU (1) | AU2005302143A1 (es) |
BR (1) | BRPI0517224A (es) |
CA (1) | CA2585658A1 (es) |
IL (1) | IL182829A0 (es) |
MX (1) | MX2007005267A (es) |
NO (1) | NO20072771L (es) |
PE (1) | PE20060610A1 (es) |
RU (1) | RU2007120392A (es) |
TW (1) | TW200631933A (es) |
WO (1) | WO2006050402A1 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004026887A2 (en) * | 2002-09-19 | 2004-04-01 | Merck & Co., Inc. | Estrogen receptor modulators |
AU2005302235A1 (en) * | 2004-11-01 | 2006-05-11 | Merck & Co., Inc. | Synthesis of 1,5-disubstituted-2-hydroxy-gibbatetraen-6-ones |
BRPI0518874A2 (pt) * | 2004-12-09 | 2008-12-16 | Merck & Co Inc | composto, composiÇço farmacÊutica, e, usos de um composto, e de uma composiÇço |
US7709508B2 (en) * | 2004-12-09 | 2010-05-04 | Merck Sharp & Dohme | Estrogen receptor modulators |
US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
CN101641013B (zh) | 2007-01-22 | 2014-07-30 | Gtx公司 | 核受体结合剂 |
US9623021B2 (en) | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
US9085566B2 (en) | 2007-02-02 | 2015-07-21 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic and related disorders |
US9187485B2 (en) | 2007-02-02 | 2015-11-17 | Baylor College Of Medicine | Methods and compositions for the treatment of cancer and related hyperproliferative disorders |
US9233941B2 (en) | 2007-02-02 | 2016-01-12 | Baylor College Of Medicine | Methods and compositions for the treatment of body weight related disorders |
JP5461197B2 (ja) | 2007-02-02 | 2014-04-02 | ベイラー カレッジ オブ メディスン | 代謝障害を処置するための組成物および方法 |
US9212179B2 (en) | 2007-02-02 | 2015-12-15 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic disorders |
ME00996B (me) | 2007-10-16 | 2012-10-20 | Repros Therapeutics Inc | Trans-klomifen za liječenje metaboličkog sindroma |
US8354446B2 (en) | 2007-12-21 | 2013-01-15 | Ligand Pharmaceuticals Incorporated | Selective androgen receptor modulators (SARMs) and uses thereof |
US20100087402A1 (en) * | 2008-09-29 | 2010-04-08 | Vivus, Inc. | Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders |
CA2865234A1 (en) | 2012-02-29 | 2013-09-06 | Repros Therapeutics Inc. | Combination therapy for treating androgen deficiency |
US9359315B2 (en) | 2013-09-10 | 2016-06-07 | Arrien Pharmaceuticals Llc | Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis |
AU2016352592B2 (en) | 2015-11-10 | 2023-04-27 | Paracrine Therapeutics Ab | Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and an anti estrogen |
BR112019001398A2 (pt) | 2016-07-29 | 2019-05-07 | Janssen Pharmaceutica Nv | métodos para tratamento de câncer de próstata |
CN110317179B (zh) * | 2018-03-29 | 2023-01-24 | 云南大学 | 类赤霉素化合物、其制备方法、药物组合物及应用及其中间体 |
WO2022140667A2 (en) * | 2020-12-23 | 2022-06-30 | Icahn School Of Medicine At Mount Sinai | Method for treating crohn's disease |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4377354A (en) | 1979-06-14 | 1983-03-22 | Conoco Inc. | Flow line bundle and method of towing same |
US4356313A (en) | 1979-10-19 | 1982-10-26 | Merck & Co., Inc. | [(5,6,9a-substituted-3-oxo-1,2,9,9a-tetrahydro-3H-fluoren-7-yl)oxy]alkanoic and cycloalkanoic acid esters and their analogs, the parent acids and their salts |
US4317922A (en) | 1979-10-19 | 1982-03-02 | Merck & Co., Inc. | [(5,6,9a-Substituted-3-oxo-1,2,9,9a-tetrahydro-3H-fluoren-7-yl)oxy]alkanoic and cycloalkanoic acids and their analogs, esters, salts and derivatives |
US4356314A (en) | 1980-06-30 | 1982-10-26 | Merck & Co., Inc. | [5,6,9A-Substituted-3-oxo-1,2,9,9a-tetrahydro-3H-fluoren-7-yl)oxy]alkanoic and cycloalkanoic acids, their analogs, esters, salts, and derivatives |
US4316043A (en) | 1980-12-19 | 1982-02-16 | Merck & Co., Inc. | [(5,6,9a-Substituted-3-oxo-1,2,9,9a-tetrahydro-3H-fluoren-7-yl)oxy]alkanoic and cycloalkanoic acids and their analogs, esters, salts and derivatives |
US4604396A (en) | 1985-09-26 | 1986-08-05 | Merck & Co., Inc. | [(2,3,9,9a-tetrahydro-3-oxo-9a-substituted-1H-fluoren-7-yl)oxy]ethanimidamides and [(2,3,9,9a-tetrahydro-3-oxo-9a-substituted-1H-fluoren-7-yl)oxy]ethanimidic acid hydrazides, their derivatives and their salts |
US4704472A (en) | 1985-12-18 | 1987-11-03 | Merck & Co., Inc. | Preparation of an enantiomer of a substituted fluorenyloxyacetic acid |
US4731472A (en) | 1986-03-03 | 1988-03-15 | Merck & Co., Inc. | (5,6-dichloro-3-oxo-9A-propyl-2,3,9,9A-tetrahydrofluoren-7-yl)alkanoic acids and alkanimidamides |
US4835313A (en) | 1986-03-03 | 1989-05-30 | Merck & Co., Inc. | (5,6-dichloro-3-oxo-9α-propyl-2,3,9,9α-tetrahydrofluoren-7-yl) alkanimidamides |
US4675341A (en) | 1986-08-13 | 1987-06-23 | Merck & Co., Inc. | [(5,6-dichloro-3-oxo-9a-propyl-2,3,9,9a-tetrahydrofluoren-7-yl)oxy]ethanol and its derivatives |
US4797391A (en) | 1986-09-24 | 1989-01-10 | Merck & Co., Inc. | ((5,6-dichloro-3-oxo-9,9a-disubstituted-2,3,9,9a-tetrahydrofluoren-7-yl)oxy)alkanoic acids and alkanimidamides |
US4731470A (en) | 1986-11-03 | 1988-03-15 | Merck & Co., Inc. | [(5,6-dichloro-3-oxo-2,9a-alkano-2,3,9,9a-tetrahydro-1H-fluoren-7-yl)oxy]alkanoic acids and alkanimidamides |
US4731471A (en) | 1986-11-03 | 1988-03-15 | Merck & Co., Inc. | (5,6-dichloro-3-oxo-2,3,9,9a-tetrahydrofluoren-7-yl)-alkanoic acids and alkanimidamides bearing novel functional 9a-substituents |
US6251898B1 (en) | 1999-08-24 | 2001-06-26 | Questcor Pharmaceuticals, Inc. | Medical use of fluorenone derivatives for treating and preventing brain and spinal injury |
ATE524170T1 (de) * | 2000-02-14 | 2011-09-15 | Merck Sharp & Dohme | Östrogenrezeptor modulatoren |
-
2005
- 2005-10-24 AR ARP050104441A patent/AR051597A1/es not_active Application Discontinuation
- 2005-10-25 TW TW094137372A patent/TW200631933A/zh unknown
- 2005-10-28 JP JP2007539314A patent/JP2008518960A/ja not_active Withdrawn
- 2005-10-28 US US11/261,692 patent/US7151196B2/en not_active Expired - Fee Related
- 2005-10-28 MX MX2007005267A patent/MX2007005267A/es not_active Application Discontinuation
- 2005-10-28 PE PE2005001265A patent/PE20060610A1/es not_active Application Discontinuation
- 2005-10-28 CN CN200580038177XA patent/CN101068764B/zh not_active Expired - Fee Related
- 2005-10-28 BR BRPI0517224-1A patent/BRPI0517224A/pt not_active Application Discontinuation
- 2005-10-28 EP EP05819550A patent/EP1809594A1/en not_active Withdrawn
- 2005-10-28 CA CA002585658A patent/CA2585658A1/en not_active Abandoned
- 2005-10-28 WO PCT/US2005/039578 patent/WO2006050402A1/en active Application Filing
- 2005-10-28 KR KR1020077009961A patent/KR20070083896A/ko not_active Application Discontinuation
- 2005-10-28 RU RU2007120392/04A patent/RU2007120392A/ru unknown
- 2005-10-28 AU AU2005302143A patent/AU2005302143A1/en not_active Abandoned
-
2007
- 2007-04-26 IL IL182829A patent/IL182829A0/en unknown
- 2007-05-31 NO NO20072771A patent/NO20072771L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US20060094779A1 (en) | 2006-05-04 |
RU2007120392A (ru) | 2008-12-10 |
WO2006050402A1 (en) | 2006-05-11 |
NO20072771L (no) | 2007-07-18 |
TW200631933A (en) | 2006-09-16 |
CN101068764A (zh) | 2007-11-07 |
MX2007005267A (es) | 2007-07-09 |
JP2008518960A (ja) | 2008-06-05 |
IL182829A0 (en) | 2007-08-19 |
US7151196B2 (en) | 2006-12-19 |
KR20070083896A (ko) | 2007-08-24 |
AU2005302143A1 (en) | 2006-05-11 |
CN101068764B (zh) | 2011-06-08 |
CA2585658A1 (en) | 2006-05-11 |
BRPI0517224A (pt) | 2008-09-30 |
PE20060610A1 (es) | 2006-08-11 |
EP1809594A1 (en) | 2007-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR051597A1 (es) | Moduladores de los receptores de estrogeno | |
BRPI0518874A2 (pt) | composto, composiÇço farmacÊutica, e, usos de um composto, e de uma composiÇço | |
DK1501819T3 (da) | Østrogenreceptormodulatorer | |
ATE524170T1 (de) | Östrogenrezeptor modulatoren | |
EP2638907A3 (en) | Combinations of an anti-HER2 antibody-drug conjugate and lapatinib | |
DE60120746D1 (de) | Östrogenrezeptormodulatoren | |
WO2006081152A3 (en) | Estrogen receptor modulators | |
ATE517871T1 (de) | Östrogenrezeptormodulatoren | |
WO2002032377A3 (en) | Estrogen receptor modulators | |
WO2004073612A3 (en) | Estrogen receptor modulators | |
WO2004091488A3 (en) | Estrogen receptor modulators | |
AR039282A1 (es) | Moduladores de receptores de estrogeno | |
DOP2005000224A (es) | Moduladores de los receptores de estrogeno | |
EA201100226A1 (ru) | Производные эстратриена, содержащие гетероциклические биоизостеры для фенольного а-кольца | |
WO2009059806A3 (en) | Preparation of 6-oxa-8alpha-steroid estrogen analogues - a new group of unnatural estrogens and their use in medicine | |
WO2005097141A3 (en) | Estrogen receptor modulators | |
WO2002032373A3 (en) | Estrogen receptor modulators | |
WO2008057309A3 (en) | Estrogen receptor modulators | |
ATE301629T1 (de) | Estrogenrezeptorliganden und verfahren | |
DOP2002000384A (es) | Moduladores de receptores estrogenicos. | |
WO2004026887A3 (en) | Estrogen receptor modulators | |
Julve et al. | Neuralgia del nervio pudendo posparto | |
CU20110018A7 (es) | Derivados de estratrieno que comprenden bioisósteros heterocíclicos para el anillo fenólico a | |
UA29208U (ru) | Способ бугайцова психологической коррекции и реабилитации женщин с раком молочной железы |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |